Sarepta Analyst Opinions

News

Roche pauses Sarepta gene therapy shipments outside U.S.

Roche pauses Sarepta gene therapy shipments outside the U.S.

Roche (OTCQX:RHHBY) has decided to pause overseas shipments of Elevidys gene therapy developed by Sarepta Therapeutics (NASDAQ:SRPT) following safety concerns raised in the U.S., Reuters reported, citing a company statement.

The Associated Press on MSN · 2d

Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy

Shares of drugmaker Sarepta Therapeutics continued to fall Tuesday after the company said it would comply with a Food and Drug Administration request to pause shipments of

Reuters · 2d

Sarepta falls after gene therapy maker pauses Elevidys shipments in US

Shares of Sarepta Therapeutics fell as much as 8% on Tuesday after the company agreed to comply with the U.S. health regulator's request to pause all shipments of its gene therapy Elevidys in the United States.

Nasdaq8mon

Analyst Expectations For Sarepta Therapeutics's Future

Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of $205.00, and a low estimate of $80.00.

Sarepta: Finally, A Little Relief For Bulls; I Expect More

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

Business Insider2y

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Quest ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Quest Diagnostics (DGX – Research Report) and Sarepta Therapeutics (SRPT – Research Report ...

Nasdaq12mon

26 Analysts Have This To Say About Sarepta Therapeutics

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

Sarepta Therapeutics' recent setbacks and restructuring have pressured Arrowhead's share price. Read why I am reiterating my bullish rating on ARWR stock.

Business Insider2y

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

Dealbreaker on MSN3d

Sarepta CEO: ‘We Have, I Believe, a Very Laudable History of Being Extraordinarily Transparent’

Financial analysts lambasted Sarepta executives for failing to disclose a drug-test fatality when the company announced a ...

TheStreet.com12y

Lazard Analyst Note on Sarepta Therapeutics Is Generating Buzz

is the subject of a research note from Lazard Capital Markets Wednesday in which analyst Bill Tanner summarizes feedback from some doctors in the Duchenne muscular ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Zimmer Biomet Holdings (ZBH) and Eli Lilly & Co (LLY)

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results